Discover

TXG
10x Genomics, Inc.
39.05
2 x 28.58
2 x 48.46
bid
ask
+
0.71
1.85%
2 @ 04:00 PM
39.17 +0.12 (0.31%)
Ytd139.42%
1y200.15%
37.65
day range
40.08
11.16
52 week range
40.08
Open38.40Prev Close38.34Low37.65High40.08Mkt Cap4.96B
Vol3.18MAvg Vol3.04MEPS-0.17P/EN/AForward P/E195.25
Beta2.11Short Ratio6.94Inst. Own111.91%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0650-d Avg27.14200-d Avg20.001yr Est27.62
Earning
DateForEstimateReportedSurprisesurprise %
2026-05-072026-030N/A0.1965.52%
2026-02-122025-120N/A0.0631.58%
2026-02-122025-120N/AN/AN/A
2025-11-062025-090N/A0.0518.52%
2025-11-062025-090N/AN/AN/A
2025-08-072025-060N/AN/AN/A
Upgrade / Downgrade
DateFirmActionFromTo
2026-07-01Piper SandlerUpgradeNeutralNeutral
2026-06-24BarclaysUpgradeOverweightOverweight
2026-05-12Morgan StanleyUpgradeEqual-WeightEqual-Weight
2026-05-12JP MorganUpgradeNeutralNeutral
2026-04-20Canaccord GenuityUpgradeBuyBuy
2026-04-20B of A SecuritiesUpgradeNeutralNeutral
Profile
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Insider Holder
DateNameRelationQuantityDescription
2026-05-21HINDSON BENJAMIN JPresident502.00KSale
2026-06-03KOSARAJU SRIDHARDirector68.28KStock Award(Grant)
2026-06-03MATEO ALAN V.Director85.88KStock Award(Grant)
2024-08-21MCANEAR JUSTIN JFormer143.24KSale
2026-06-03POPOVITS KIMBERLY JDirector37.45KStock Award(Grant)
2026-06-21SAXONOV SERGE WILSONChief Executive Officer1.39MSale
Institution Ownership
Report DateOrganizationPositionValuePercentage
2026-03-30FMR, LLC17.74M692.78M15.18%
2026-03-30ARK Investment Management, LLC11.72M457.56M10.03%
2026-03-30Blackrock Inc.10.08M393.62M8.62%
2026-03-30Vanguard Portfolio Management LLC6.91M269.95M5.91%
2026-03-30Quantinno Capital Management, LP5.41M211.33M4.63%
2026-03-30Vanguard Capital Management LLC5.27M205.78M4.51%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2026-05-30ARK ETF Trust-ARK Innovation ETF7.03M274.46M6.01%
2026-03-30VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.75M146.28M3.20%
2026-05-30ARK ETF Trust-ARK Genomic Revolution ETF2.89M112.92M2.47%
2026-03-30VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.71M105.84M2.32%
2026-04-29iShares Trust-iShares Russell 2000 ETF2.65M103.38M2.27%
2026-05-30Fidelity Select PORT.s-Select Medical Technology and Devices PORT.2.07M80.65M1.77%
Split
SplitDate
1 : 22006-07-17
2 : 12006-07-16